An interventional study of Control Strategy and Personalized precision ICD implantation Strategy based in genetic findings and CMR results in Non-ischemic Dilated Cardiomyopathy, sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER). Recruiting at 31 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-28.
Sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER) · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Cardiomyopathy, Dilated with a site in Spain — 6 open to participants now, 9 under way, 3 of them phase 3. Cardiomyopathy, Dilated · Spain.
Among the 20 studies in Cardiomyopathy, Dilated with a site in Spain, this one has the largest planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2023, is one of 2 with no phase, and was the 15th registered.
256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.
Browse Cardiomyopathy, Dilated studies →6 of the 20 studies in Cardiomyopathy, Dilated with a site in Spain are open now. Recruiting first, the newest first:
Kardigan, Inc. · Sites in Spain, United States, Belgium and 8 more countries
Ages 18+
Kardigan, Inc. · Sites in Spain, United States, Belgium and 8 more countries
Ages 18+
Alexion Pharmaceuticals, Inc. · Sites in Spain, United States, Italy and 1 more country
Ages 18–70
Centro Medico Teknon · Sites in Spain, Italy, Portugal
Ages 18+
Cristina Avendaño Solá · Sites in Spain
Ages 18–64
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 54 Cardiomyopathy, Dilated studies recruiting now, 31 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 14 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 5 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 900 is above the median of 43 across 145 interventional studies indexed under Cardiomyopathy, Dilated.
Median enrollment 70 across the 13 interventional studies, 200 across the 7 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 20 have an industry lead sponsor. The 10 most frequent:
Consorcio Centro de Investigación Biomédica en Red (CIBER) is the lead sponsor of 18 studies on the registry; 6 are open to participants now.
Consorcio Centro de Investigación Biomédica en Red (CIBER) has 1 study filed under Cardiomyopathy, Dilated — fewer than ten, so there is no comparison to draw.
2 of the studies in Cardiomyopathy, Dilated with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07210723Phase 3Kardigan, Inc.A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | 2027-09 |
| NCT05981092Alexion Pharmaceuticals, Inc.A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM) | 2027-08-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Cardiomyopathy, Dilated with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prospective, randomised, multicentre, open-label study to assess the non-inferiority of a personalised precision strategy for Sudden Cardiac Death (SCD) prevention in patients with non-ischemic dilated cardiomyopathy with Left Ventricular Ejection Fraction (LVEF) ≤35%
Prospective, randomised, multicentre, open-label study to assess the non-inferiority of a personalised precision strategy for SCD prevention in patients with non-ischemic dilated cardiomyopathy with LVEF≤35%
Randomization will be 1:1 and patients are allocated to either control strategy or intervention strategy.
In the control strategy group, patients will get an Implantable Cardioverter Defibrillator (ICD) implanted. Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a Dilated Cardiomyopathy DCM-causing pathogenic or likely pathogenic genetic variants or Late Gadolinium Enhancement (LGE) in Cardiac Magnetic Resonance (CMR). Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Control Strategy
Other: Personalized precision ICD implantation Strategy based in genetic findings and CMR results
ICDs will be implanted in all patients according to current recommendations
Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a DCM-causing pathogenic or likely pathogenic genetic variants or LGE in CMR. Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.
Composite end-point of all cause death, hospitalization due to device-related complications, and non-fatal major arrhythmic events.
Time frame: 4 years
All-cause death
Time frame: 4 years
SCD
Time frame: 4 years
Hospitalisation for device-related complications
Time frame: 4 years
Non-fatal major arrhythmic events
Time frame: 4 years
cost-effectiveness
Incremental Cost-effectiveness ratio (ICER) of personalized ICD allocation strategy in non-ischemic DCM \[ Time Frame: The time horizon of the evaluation will be limited to 4 years \] The ICER of the personalized ICD allocation strategy compared with standard strategy is defined as the ratio between the variation in costs and the variation in effectiveness between both strategy groups. In the personalized strategy group, costs will include those related to personalization tests (CMR and genetic analysis) plus costs related to implanting and carrying an ICD (in the number of patients who eventually receive a device). In the control group, costs will include only the latter concept. Costs will be measured in Euros. The variation in effectiveness will be measured both in terms of life years gained, measured in years, and in terms of quality of life gained, measured in QALY. In the first case, ICER will be measured as Euros/year; in the second, it will be measured as Euros/QALY.
Time frame: 4 years
Quality of life assessed by KCCQ, EQ-5D and HADS
Time frame: 4 years
Started Sep 2023 (actual). Primary completion is estimated for Oct 2025, 24 months after the start.
Of 28 interventional studies with no phase under Cardiomyopathy, Dilated, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 73. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Consorcio Centro de Investigación Biomédica en Red (CIBER)